# A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight

> **NCT04447261** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 87 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** BI 1356225
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04447261
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-30
- **Primary completion:** 2021-04-25
- **Final completion:** 2021-04-25
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2021-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447261, "A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or Overweight". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04447261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*